Stock information and investor decision center

How to research BioVie

Start with current SEC filings, then review the study designs and source-linked scientific evidence. Compare potential milestones with financing needs, dilution, clinical uncertainty, regulatory risk and the possibility that a program does not advance.

Current milestones to monitor

• SUNRISE-PD Phase 2 topline results targeted for calendar Q3 2026, according to BioVie’s May 18, 2026 release.
• ADDRESS-LC Phase 2 topline results targeted for late summer 2026, according to BioVie’s May 26, 2026 release.
• Clinical data quality, effect size, safety, regulatory feedback and financing are more important than headline timing alone.

Reasons investors may follow the company

• Two differentiated investigational candidates across neurology and hepatology
• Near-term Phase 2 data milestones
• Government-funded Long COVID research
• Potential partnering paths for development programs

Risks investors must weigh

• No approved BioVie products and no product-sales revenue
• Clinical studies may fail, produce mixed data or require additional trials
• Regulatory approval is uncertain and may never occur
• Additional financing may dilute existing holders
• A small-cap biotechnology stock can be highly volatile
• Litigation, intellectual-property, execution and third-party risks

How shares are purchased

BioVie does not sell exchange-traded shares directly through this website. Investors typically purchase or sell NASDAQ-listed securities through a regulated brokerage account. Before acting, confirm the ticker, order type, fees and risks with the brokerage and consider consulting a licensed financial professional.

No recommendation

BioVie and this website do not recommend that any person buy, hold or sell BIVI, BIVIW or any other security. This page is educational, is not individualized and is not investment, tax or legal advice.